Implications of Molecular Classifications in Glioma Surgery

Overview

Journal J Neurooncol

Publisher Springer

Date 2024 Nov 12

PMID 39532825

Authors

Anita L Kalluri

Joyce H Lee

Calixto-Hope G Lucas

Jordina Rincon-Torroella

Chetan Bettegowda

Affiliations

Soon will be listed here.

Abstract

Purpose: The incorporation of molecular markers into neuro-oncology has transformed our understanding of adult diffuse gliomas. While surgical resection is the mainstay of treatment for many patients with gliomas, surgical management strategies warrant re-exploration in the context of characteristic molecular profiles.

Methods: We reviewed the neurosurgical and neuro-oncological literature for studies investigating surgery in molecularly defined cohorts of adult diffuse gliomas.

Results: We discuss key molecular markers associated with the three subtypes of adult diffuse glioma: glioblastoma IDH-wildtype, astrocytoma IDH-mutant, and oligodendroglioma IDH-mutant and 1p/19q codeleted. We additionally discuss surgical strategies and extent of resection in these tumors, framing them in the context of key molecular alterations. Finally, we briefly discuss the practical utility of molecular markers in guiding surgical decision making.

Conclusion: Molecular markers in gliomas are of growing relevance to surgical intervention. Advancements in preoperative and intraoperative molecular diagnostics will increase the utility of molecular biomarkers in informing surgical decision-making for patients with gliomas.

Citing Articles

Sphingosine kinase 1 promotes M2 macrophage infiltration and enhances glioma cell migration via the JAK2/STAT3 pathway.

Song Z, Zhao Z, Liu X, Song Y, Zhu S, Jia Z Sci Rep. 2025; 15(1):4152.

PMID: 39900970 PMC: 11790894. DOI: 10.1038/s41598-025-88328-2.

References

Ostrom Q, Price M, Neff C, Cioffi G, Waite K, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2023; 25(12 Suppl 2):iv1-iv99. PMC: 10550277. DOI: 10.1093/neuonc/noad149. View

Brat D, Aldape K, Colman H, Holland E, Louis D, Jenkins R . cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol. 2018; 136(5):805-810. PMC: 6204285. DOI: 10.1007/s00401-018-1913-0. View

Eckel-Passow J, Lachance D, Molinaro A, Walsh K, Decker P, Sicotte H . Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015; 372(26):2499-508. PMC: 4489704. DOI: 10.1056/NEJMoa1407279. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Alnahhas I, Alsawas M, Rayi A, Palmer J, Raval R, Ong S . Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020; 2(1):vdaa082. PMC: 7596890. DOI: 10.1093/noajnl/vdaa082. View

Young J, Morshed R, Hervey-Jumper S, Berger M . The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions. Neuro Oncol. 2023; 25(12):2117-2133. PMC: 10708937. DOI: 10.1093/neuonc/noad133. View

Delgado-Martin B, Medina M . Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment. Adv Sci (Weinh). 2020; 7(9):1902971. PMC: 7201267. DOI: 10.1002/advs.201902971. View

Zhang K, Wang X, Zhou B, Zhang L . The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam Cancer. 2013; 12(3):449-58. DOI: 10.1007/s10689-013-9607-1. View

Brennan C, Verhaak R, McKenna A, Campos B, Noushmehr H, Salama S . The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462-77. PMC: 3910500. DOI: 10.1016/j.cell.2013.09.034. View

10.

Wang H, Zhang X, Liu J, Chen W, Guo X, Wang Y . Clinical roles of amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumors. Front Neurosci. 2024; 18:1308627. PMC: 11002900. DOI: 10.3389/fnins.2024.1308627. View

11.

Giunco S, Padovan M, Angelini C, Cavallin F, Cerretti G, Morello M . Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients. ESMO Open. 2023; 8(3):101570. PMC: 10265608. DOI: 10.1016/j.esmoop.2023.101570. View

12.

Han F, Hu R, Yang H, Liu J, Sui J, Xiang X . PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis. Onco Targets Ther. 2016; 9:3485-92. PMC: 4913532. DOI: 10.2147/OTT.S99942. View

13.

Sanai N, Polley M, McDermott M, Parsa A, Berger M . An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115(1):3-8. DOI: 10.3171/2011.2.jns10998. View

14.

Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H . Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7(5):392-401. DOI: 10.1016/S1470-2045(06)70665-9. View

15.

Beiko J, Suki D, Hess K, Fox B, Cheung V, Cabral M . IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2013; 16(1):81-91. PMC: 3870823. DOI: 10.1093/neuonc/not159. View

16.

Roder C, Stummer W, Coburger J, Scherer M, Haas P, von der Brelie C . Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial. J Clin Oncol. 2023; 41(36):5512-5523. PMC: 10730068. DOI: 10.1200/JCO.22.01862. View

17.

Ji S, Kim J, Park C . Experience Profiling of Fluorescence-Guided Surgery I: Gliomas. Brain Tumor Res Treat. 2019; 7(2):98-104. PMC: 6829086. DOI: 10.14791/btrt.2019.7.e38. View

18.

Drexler R, Sauvigny T, Schuller U, Eckhardt A, Maire C, Khatri R . Epigenetic profiling reveals a strong association between lack of 5-ALA fluorescence and amplification in -wildtype glioblastoma. Neurooncol Pract. 2023; 10(5):462-471. PMC: 10502788. DOI: 10.1093/nop/npad025. View

19.

Coburger J, Scheuerle A, Pala A, Thal D, Wirtz C, Konig R . Histopathological Insights on Imaging Results of Intraoperative Magnetic Resonance Imaging, 5-Aminolevulinic Acid, and Intraoperative Ultrasound in Glioblastoma Surgery. Neurosurgery. 2017; 81(1):165-174. DOI: 10.1093/neuros/nyw143. View

20.

Karschnia P, Vogelbaum M, van den Bent M, Cahill D, Bello L, Narita Y . Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021; 149:23-33. DOI: 10.1016/j.ejca.2021.03.002. View